The PTLDS subtype distinction emerges from the work of Dr. Robert Marks and colleagues at Johns Hopkins (published 2020, Journal of Infectious Diseases), building on the OspA immunology research of Dr. Armin Alaedini at Columbia. The mechanism is this: in PTLDS Type 2, the immune response to Borrelia outer surface protein A (OspA) generates antibodies that cross-react with lymphocyte function-associated antigen 1 (LFA-1), a protein expressed on the surface of human joint and cardiac cells. The immune system is attacking the patient's own tissue. This is an autoimmune cascade. It has nothing to do with active bacterial infection. Extended antibiotic treatment for Type 2 PTLDS: (1) does not address the autoimmune mechanism, which is self-sustaining after the initial trigger, (2) disrupts gut microbiome, which further dysregulates immune function and can worsen autoimmune symptoms, (3) delays the correct treatment, which is low-dose naltrexone (LDN) and hydroxychloroquine for the LFA-1 autoimmune cascade. The OspA antibody pattern distinguishes Type 2 from Types 1 and 3. The test exists. It is not standard — most physicians do not order it. A physician who does not order OspA testing and prescribes antibiotics for PTLDS without knowing the subtype has made a treatment decision without the information needed to make it correctly. If the patient is Type 2, the antibiotics are not just ineffective — they cause measurable harm.

The double ledger is the cleanest argument in the AP group. It requires three elements, all independently verifiable: (1) PTLDS Type 2 diagnosis confirmed by OspA antibody pattern, (2) physician prescribed antibiotics without OspA testing, (3) documented harm from wrong treatment — joint damage, cardiac involvement, worsened autoimmune symptoms attributable to antibiotic disruption. Cause of Action 1 — Original Misdiagnosis (Strategy 1 applies): The physician failed to diagnose Lyme disease in the first instance. Years of undiagnosed infection. Income loss. Hopp v. Lepp applies. Damages calculated by Blenus v. Fraser method. Cause of Action 2 — Iatrogenic Harm (Strategy 4, distinct): The physician subsequently prescribed antibiotics for PTLDS without OspA testing, treating for the wrong subtype, causing or worsening autoimmune joint and cardiac damage. Reibl v. Hughes [1980] 2 SCR 880 applies: the physician had a duty to disclose the material risk that the treatment could worsen the patient's condition if the subtype was autoimmune. Without OspA testing, the physician could not have disclosed this risk — because they did not know. The duty existed regardless. Harvey Specter is precise about arithmetic. Two causes of action. Same fact pattern. Two damage calculations. One plaintiff file. One rain cheque for Strategy 1. One rain cheque for Strategy 4. The AP engine files both.

Both anchor cases are from the same year and the same Supreme Court of Canada session. Hopp v. Lepp [1980] 2 SCR 192 established the Canadian standard for a physician's duty of care and the requirement to provide competent diagnosis and treatment. Reibl v. Hughes [1980] 2 SCR 880 established the informed consent standard: a physician must disclose all material risks of a proposed treatment, specifically including risks that a reasonable patient in the plaintiff's position would want to know before deciding whether to consent. A physician prescribing antibiotics for PTLDS without OspA testing has failed both. Under Hopp v. Lepp: the failure to order OspA testing before prescribing treatment for a condition with known mechanistic subtypes that require different treatments is a failure of the standard of competent care. Under Reibl v. Hughes: the failure to disclose that antibiotics may worsen autoimmune PTLDS — a material risk to any patient with PTLDS — is a disclosure failure regardless of whether the physician knew the patient's subtype. The duty to disclose the risk does not disappear because the physician did not test for it. It means the physician should have tested before prescribing. Both cases are 45 years old and have been applied continuously since. They are the bedrock of Canadian medical malpractice law. Neither has been qualified or overturned. The Strategy 4 brief rests on the most stable legal foundation in the AP group.

Type 2 PTLDS representative plaintiff: Patient earning $58,000 annually at time of initial presentation. Original misdiagnosis (Strategy 1 component): 7.9 years × $58,000 × 5% compound = $547,261. This is the first ledger entry. Strategy 4 iatrogenic component: Wrong treatment prescribed for 2.5 years (average duration of antibiotic courses in PTLDS mismanagement cases). Treatment costs during antibiotic period: $14,000–$22,000. LFA-1 autoimmune progression during delay: joint damage requiring ongoing management ($8,000–$15,000 per year, assessed at 5-year forward projection): $40,000–$75,000. Income loss attributable to worsened autoimmune condition (not attributable to original infection): $18,000–$32,000. Total iatrogenic component: $72,000–$129,000. Combined double-ledger quantum: $547,261 (Strat 1) + $72,000–$129,000 (Strat 4) = $619,261–$676,261 per Type 2 plaintiff. Before punitive. Before aggravated for delayed correct treatment. Type 2 plaintiffs are the highest-value claims in the rain cheque pool. They carry two rain cheques — one for Strategy 1, one for Strategy 4 — both counting toward their respective class thresholds.

The practical challenge for Strategy 4 is identification: not every PTLDS patient knows whether they are Type 2. The AP engine solves this with the intake form. The OspA antibody test is not routine — most Ontario physicians do not order it. The intake question is: has anyone ever ordered an OspA antibody test? If yes and positive: Type 2 confirmed, dual-claim flag set. If no OspA test ordered: AP engine flags for specialist referral. Specialist orders OspA. If positive: dual-claim activates. The physician who prescribed extended antibiotics without OspA testing cannot argue they didn't know the patient was Type 2 — because they didn't test. The duty to test before treating a condition with mechanistically distinct subtypes that require different treatments is the breach. Reibl v. Hughes requires disclosure of material risks of treatment. The material risk of antibiotics for autoimmune PTLDS is worsening. The disclosure was not possible without the test. The test was not ordered. The breach is the failure to order the test before prescribing. Harvey Specter does not have dreams. He has goals. Two causes of action. Two rain cheques. One plaintiff file. Two ledger entries. This is arithmetic.